glp-1 receptor agonist after roux-en-y gastric bypass Interest in Treatment with Agonists for the Management of Insufficient Weight Loss or Weight Regain Bariatric Surgery | Obesity Surgery Efficacy of the Glucagon-Like Peptide-1
Description
This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database
The primary outcome was change in HbA1c from baseline
In recent years, weight-loss drugs have become a common addition to diet and exercise routines.
As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy
Society guidelines have left clinicians with some questionable recommendations
